Biologic treatments for Crohn’s disease are expanding as European regulators near decisions on adalimumab and certolizumab, while other alternatives face distinct clinical hurdles in efficacy and neurological safety.
Trials Advance Biologic Therapies for Crohn Disease
- Biologic Expansion: Multiple therapies are at various stages of evaluation and development for the biological treatment of Crohn’s disease.
- Regulatory Milestones: Phase III trials have established the efficacy of adalimumab and certolizumab in inducing and maintaining response and remission, bringing the prospect of European marketing authorization close.
- Safety Barriers: Natalizumab faces neurological safety concerns that compromise its commercialization in Crohn’s disease for now, while data on visilizumab remain preliminary.
Subcutaneous Anti-TNF Agents Approach European Authorization
A growing number of new molecules are at various stages of evaluation and development for the biological treatment of Crohn’s disease. Subcutaneous anti-TNF-alpha agents such as adalimumab and certolizumab have advanced through Phase III clinical trials, which validated both drugs. They induce and maintain clinical response and remission in Crohn’s disease, and the prospect of European marketing authorization seems close.
Adalimumab, known under the brand name Humira, and certolizumab, known as Cimzia, are injectable subcutaneous anti-TNF-alpha agents.
Neurological Safety Concerns Compromise Natalizumab Commercialization
Beyond anti-TNF approaches, other biological agents are being evaluated. Fontolizumab, targeting interferon gamma, remains to be evaluated in Phase III trials. Natalizumab, a monoclonal antibody blocking leukocyte adhesion, has had its commercialization in Crohn’s disease compromised for now by neurological tolerance concerns. Data concerning visilizumab, an anti-CD3 antibody, are still preliminary.
| Biologic Molecule | Target Pathway | Administration Route | Clinical Development Stage |
|---|---|---|---|
| Adalimumab (Humira) | Anti-TNF-alpha | Subcutaneous | Phase III validated; European authorization near |
| Certolizumab (Cimzia) | Anti-TNF-alpha | Subcutaneous | Phase III validated; European authorization near |
| Fontolizumab | Interferon gamma | — | Phase III evaluation |
| Natalizumab | Leukocyte adhesion | — | Commercialization compromised by neurological safety |
| Visilizumab | Anti-CD3 | — | Preliminary data |
